Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14 2024 - 7:30AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced that it will host an in-person Clinical Showcase on
Wednesday, February 21, 2024. The event will take place from 10
a.m.-noon ET at the Nasdaq Market Site in Times Square, New York
City.
The Clinical Showcase will provide an opportunity to learn more
about the upcoming Phase 3 trial of OCU400—including more specifics
on study design and the broad indication for the treatment of
retinitis pigmentosa, as well as a clinical study update from the
ongoing Phase 1/2 trial of OCU400. A panel discussion will offer
background on the genesis of modifier gene therapy and how this
potential first-in-class treatment approach has evolved from the
lab into the clinic.
Ocugen presenters include:
- Dr. Shankar Musunuri, Chairman, CEO & Co-founder
- Mike Shine, SVP Commercial
- Dr. Arun Upadhyay, CSO & Head of R&D
Panelists include:
- Dr. Lejla Vajzovic, Associate Professor of Ophthalmology with
Tenure, Director of Duke Vitreoretinal Fellowship Program at Duke
Eye Center and Duke University School of Medicine
- Dr. Byron Lam, Professor of Ophthalmology, Dr. Mark J. Daily,
Endowed Chair in Ophthalmology at the University of Miami
- Dr. Neena Haider, inventor of modifier gene therapy, CEO &
CSO Shifa Precision, faculty at Harvard Medical School
- OCU400 Phase 1/2 clinical trial
patient who has completed 12 months of therapy
Nasdaq requires advance registration from attendees and
registration can be done by contacting Tiffany Hamilton at
Tiffany.Hamilton@ocugen.com.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on X and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks, and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact:Tiffany HamiltonHead of
CommunicationsIR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024